

# **Early versus Late Lactoferrin in Prevention of Neonatal Sepsis**

*Thesis*

Submitted for Partial Fulfillment of M.Sc. Degree  
in Pediatrics

*Presented by*

**Atef Nagy Mohamed**

(M. B. B. C. H.)  
Ain Shams University

*Under Supervision of*

**Prof. Dr. Hisham Abd El-Samie Awad**

*Professor of Pediatrics  
Faculty of Medicine – Ain Shams University*

**Prof. Dr. Ghada Ibrahim Gad**

*Professor of Pediatrics  
Faculty of Medicine – Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا أنك لا تعلم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Hisham Abd El-Samie Awad**, Professor of Pediatrics - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Ghada Ibrahim Gad**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I would like to express my hearty thanks to all my family for their support till this work was completed, My Dad your guiding hands on my shoulder will remain with me forever.*

*Last but not least my sincere thanks and appreciation to all patients participated in this study.*

*Atef Nagy Mohamed*

# *List of Contents*

Title	Page No.
List of Tables .....	5
List of Figures .....	8
List of Abbreviations .....	10
Abstract .....	x
Introduction .....	1
Aim of the Work.....	4
Review of Literature	
Chapter (1): Premature Infants .....	5
Chapter (2): Neonatal Sepsis .....	13
Chapter (3): Necrotizing Enterocolitis.....	28
Chapter (4): Lactoferrin .....	33
Subjects and Methods .....	46
Results .....	61
Discussion .....	107
Summary .....	119
Conclusion.....	123
Recommendations .....	124
References .....	125
Arabic Summary	

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Short and Long-term complications of preterm infant. ....	8
<b>Table (2):</b>	Common organisms causing neonatal infections. ....	15
<b>Table (3):</b>	Sepsis score; examination of clinical and hematological symptoms in neonatal sepsis ....	19
<b>Table (4):</b>	Diagnostic markers of infection for preterm and newborn infants. ....	20
<b>Table (5):</b>	Seven points hematological scoring system ....	21
<b>Table (6):</b>	Modified Bell's criteria for staging Necrotizing Enterocolitis. ....	30
<b>Table (7):</b>	Lactoferrin concentrations in human secretions. ....	38
<b>Table (8):</b>	Sepsis score examination of clinical and hematological symptoms in neonatal sepsis. ....	54
<b>Table (9):</b>	Hematological sepsis score. ....	55
<b>Table (10):</b>	Demographic characteristics of the studied neonates ....	64
<b>Table (11):</b>	Comparison between Early lactoferrin group, late lactoferrin group and control group as regard resuscitation ....	65
<b>Table (12):</b>	Comparison between early lactoferrin group, late lactoferrin group and control group as regard symptoms of feeding intolerance. ....	66
<b>Table (13):</b>	Comparison between studied groups as regard age of full enteral intake, feeding stoppage and duration. ....	67
<b>Table (14):</b>	Comparison between studied groups as regard type of formula. ....	70

## *List of Tables (cont....)*

Table No.	Title	Page No.
<b>Table (15):</b>	Comparison between studied groups as regard amount of breast feeding to artificial formula. ....	71
<b>Table (16):</b>	Comparison between Early lactoferrin group, late lactoferrin group and control group as regard Necrotizing enterocolitis incidence and staging. ....	72
<b>Table (17):</b>	Laboratory data of the studied neonates as regard CBC and CRP upon admission. ....	73
<b>Table (18):</b>	Laboratory data of the studied neonates as regard CBC and CRP upon development of sepsis. ....	74
<b>Table (19):</b>	Comparison between Early lactoferrin group, late lactoferrin group and control group as regard Development of sepsis. ....	76
<b>Table (20):</b>	Laboratory data of the studied neonates as regard blood culture and sepsis score upon development of sepsis. ....	78
<b>Table (21):</b>	Comparison between studied groups as regard Radiological, Ultrasound and Echocardiography findings. ....	81
<b>Table (22):</b>	Comparison between studied groups as regard NICU treatment and procedures. ....	83
<b>Table (23):</b>	Comparison between studied groups as regard long term outcome ....	86
<b>Table (24):</b>	Laboratory data of the studied neonates as regard Serum ferritin level. ....	88
<b>Table (25):</b>	Comparison between studied groups as regard Mortality. ....	89
<b>Table (26):</b>	Correlation of Ballard score to age of full enteral intake, day of development of sepsis and NICU stay duration in the studied groups. ....	91

## *List of Tables (Cont....)*

Table No.	Title	Page No.
<b>Table (27):</b>	Correlation of age of full enteral intake to NEC day of life, day of development of sepsis and NICU stay duration in the studied groups. ....	93
<b>Table (28):</b>	Correlation of Day of development of sepsis to Birth wt and Duration of TPN days in the studied groups. ....	94
<b>Table (29):</b>	Correlation of Apgar score at 1 <sup>st</sup> minute to NICU stay duration in the studied groups. ....	95
<b>Table (30):</b>	Correlation age of full enteral intake to day of development of sepsis and NICU stay duration, duration of TPN and Rodwell and Tollner scores. ....	96
<b>Table (31):</b>	Correlation of S.Ferritin to HB, HCT, CRP and duration of TPN. ....	99
<b>Table (32):</b>	Correlation between TLC and some medical aspects of studied neonates. ....	100
<b>Table (33):</b>	Comparison between sepsis and non-sepsis group as regard age of full enteral intake NICU procedures, duration of TPN, length of hospital stay and outcome. ....	101
<b>Table (34):</b>	Comparison between survivors and non-survivors groups as regard age of full enteral intake, NICU treatment, procedures and long term outcome. ....	104

## *List of Figures*

Fig. No.	Title	Page No.
<b>Fig. (1):</b>	Structure of Lactoferrin.....	34
<b>Fig. (2):</b>	Iron uptake, transport, delivery and recycling in the human body.....	37
<b>Fig. (3):</b>	Mechanism of antibacterial action of lactoferrin.....	40
<b>Fig. (4):</b>	Mechanism of antiviral action of lactoferrin.....	41
<b>Fig. (5):</b>	Consort chart of neonates included in the study.....	62
<b>Fig. (6):</b>	Age of full enteral intake in different studied groups.....	68
<b>Fig. (7):</b>	Frequency of feeding stoppage in different studied groups.....	69
<b>Fig. (8):</b>	Total days of feeding stoppage in different studied groups.....	69
<b>Fig. (9):</b>	TLC and CRP in different studied groups.....	75
<b>Fig. (10):</b>	Development of sepsis in different study groups. ....	77
<b>Fig. (11):</b>	Blood cultures results in different studied groups. ....	79
<b>Fig. (12):</b>	Causative organisms according to blood culture results.....	80
<b>Fig. (13):</b>	Rodwell score and Tollner score in different studied groups.....	80
<b>Fig. (14):</b>	Abdominal X ray findings in different studied groups.....	82
<b>Fig. (15):</b>	TPN duration in different studied groups.....	84
<b>Fig. (16):</b>	NICU stay duration in different studied groups. ....	85
<b>Fig. (17):</b>	DIC incidence in different studied groups.....	87
<b>Fig. (18):</b>	Outcome in different studied groups. ....	90
<b>Fig. (19):</b>	Negative correlation between Ballard score and age of full enteral intake in the studied groups. ....	92



## *List of Figures (cont...)*

Fig. No.	Title	Page No.
<b>Fig. (20):</b>	Negative correlation between Ballard score and NICU stay duration in the studied groups. ....	92
<b>Fig. (21):</b>	Positive correlation between Age of full enteral intake and Nicu stay duration in the studied groups. ....	93
<b>Fig. (22):</b>	Negative correlation between Apgar score at 1st minute and NICU stay duration in the studied groups. ....	95
<b>Fig. (23):</b>	Positive correlation between age of full enteral intake and length of hospital stay.....	97
<b>Fig. (24):</b>	Positive correlation between age of full enteral intake and Tollner score.....	97
<b>Fig. (25):</b>	Positive correlation between age of full enteral intake and duration of TPN.....	98
<b>Fig. (26):</b>	Negative correlation between TLC and feeding stop duration.....	100
<b>Fig. (27):</b>	Comparison between outcome results as regard development of sepsis .....	102
<b>Fig. (28):</b>	Comparison between blood products transfusion percentage as regard development of sepsis.....	102
<b>Fig. (29):</b>	Comparison between age of full enteral intake, duration of TPN, and length of hospital stay as regard development of sepsis.....	103
<b>Fig. (30):</b>	Comparison between outcome as regard duration of TPN. ....	105
<b>Fig. (31):</b>	Comparison between outcome as regard blood products transfusion.....	105
<b>Fig. (32):</b>	Comparison between outcome as regard pulmonary hemorrhage incidence.....	106
<b>Fig. (33):</b>	Comparison between outcome as regard DIC incidence.....	106

## *List of Abbreviations*

<b>Abb.</b>	<b>Full term</b>
<i>AAP</i> .....	<i>American Academy of Pediatrics</i>
<i>ARDS</i> .....	<i>Acquired respiratory distress syndrome</i>
<i>BLF</i> .....	<i>Bovine lactoferrin</i>
<i>BPD</i> .....	<i>Bronchopulmonary dysplasia</i>
<i>CBC</i> .....	<i>Complete blood count</i>
<i>CDC</i> .....	<i>Centers for Disease Control and Prevention</i>
<i>CRP</i> .....	<i>C reactive protein</i>
<i>CSF</i> .....	<i>Cerebrospinal fluid</i>
<i>CXR</i> .....	<i>Chest x ray</i>
<i>DIC</i> .....	<i>Disseminated intravascular coagulation</i>
<i>DM</i> .....	<i>Diabetes mellitus</i>
<i>DNA</i> .....	<i>Deoxyribonucleic acid</i>
<i>ECHO</i> .....	<i>Echocardiography</i>
<i>E-Coli</i> .....	<i>Escherichia coli</i>
<i>ELBW</i> .....	<i>Extremely low birth weight</i>
<i>EOS</i> .....	<i>Early onset sepsis</i>
<i>EPO</i> .....	<i>Erythropoietin</i>
<i>ETT</i> .....	<i>Endotracheal tube</i>
<i>GBS</i> .....	<i>Group B streptococci</i>
<i>G-CSF</i> .....	<i>Granulocyte colony-stimulating factor</i>
<i>Hb</i> .....	<i>Hemoglobin</i>
<i>HCT</i> .....	<i>Hematocrit</i>
<i>HLF</i> .....	<i>Human lactoferrin</i>
<i>IAP</i> .....	<i>Intrapartum antibiotics prophylaxis</i>
<i>IFN</i> .....	<i>Interferon</i>
<i>IL</i> .....	<i>Interleukin</i>

## *List of Abbreviations (Cont....)*

<b>Abb.</b>	<b>Full term</b>
<i>LBW</i> .....	<i>Low birth weight</i>
<i>LF</i> .....	<i>Lactoferrin</i>
<i>LGG</i> .....	<i>Lactobacillus Rhamnosus GG</i>
<i>LOS</i> .....	<i>Late onset sepsis</i>
<i>LPS</i> .....	<i>Lipopolysaccharide</i>
<i>LSCS</i> .....	<i>Lower segment cesarean section</i>
<i>NEC</i> .....	<i>Necrotizing enterocolitis</i>
<i>NICU</i> .....	<i>Neonatal intensive care unit</i>
<i>NPO</i> .....	<i>Nil per Os</i>
<i>NS</i> .....	<i>Neonatal sepsis</i>
<i>PAI-1</i> .....	<i>Plasminogen activator inhibitor-1</i>
<i>PAMG-1</i> .....	<i>Placental alpha microglobulin-1</i>
<i>pH</i> .....	<i>Power of hydrogen</i>
<i>PLT</i> .....	<i>Platelets.</i>
<i>PMN</i> .....	<i>Poly morphnuclear cells</i>
<i>PPV</i> .....	<i>Positive pressure ventilation</i>
<i>Pulm hge</i> .....	<i>Pulmonary hemorrhage</i>
<i>RDS</i> .....	<i>Respiratory distress syndrome</i>
<i>rhTFF3</i> .....	<i>Recombinant human Trefoil Factor 3</i>
<i>ROP</i> .....	<i>Retinopathy of prematurity</i>
<i>S. Ferritin</i> .....	<i>Serum ferritin.</i>
<i>sICAM-1</i> .....	<i>Soluble intracellular adhesion molecules-1</i>
<i>SD</i> .....	<i>Standard deviation</i>
<i>SGA</i> .....	<i>Small for gestational age</i>
<i>SPSS</i> .....	<i>Statistical Program for social science</i>
<i>SVD</i> .....	<i>Spontaneous vaginal delivery</i>
<i>t PA</i> .....	<i>Tissue plasminogen activator</i>
<i>TAT</i> .....	<i>Thrombin – antithrombin III complex</i>

## *List of Abbreviations (cont...)*

<b>Abb.</b>	<b>Full term</b>
<i>TLC.....</i>	<i>Total leucocytic count</i>
<i>TNF alpha .....</i>	<i>Tumor necrosis factor alpha</i>
<i>TPN.....</i>	<i>Total parenteral nutrition</i>
<i>U/S.....</i>	<i>Ultrasound</i>
<i>VLBW.....</i>	<i>Very low birth weight</i>
<i>WBC.....</i>	<i>White blood cells</i>

## Abstract

**Background:** sepsis related morbidity and mortality is a concern in neonatal intensive care units (NICUs) specially in preterm and low birth weight (LBW) infants who are more vulnerable due to immaturity of immune defenses and protective barriers. Lactoferrin is the main whey protein in mammalian milk, and is involved in innate immune host defenses. In vitro, Bovine lactoferrin (BLF) shows potent direct antimicrobial activity against all types of pathogens, which occurs via anti-cell wall actions and leads to disintegration of the micro-organism's membranes. BLF is also synergistic with many antimicrobials and antifungals, and promotes growth and differentiation of the immature gut.

**Objective:** to evaluate the effectiveness of oral bovine lactoferrin in prevention of neonatal sepsis and feeding intolerance in preterm neonates with comparison of early (1<sup>st</sup> day) versus late (48-72 hours) lactoferrin administration; secondary aim was to study effect of lactoferrin supplementation on serum ferritin and follow up long term outcome (broncho-pulmonary dysplasia, retinopathy of prematurity and necrotizing enterocolitis).

**Patient & methods:** A prospective randomized, single blind, placebo controlled study was carried out on 180 preterm neonates admitted to the Neonatal Intensive Care Units of Ain Shams University Hospitals and Shobra General Hospital in the period from August 2014 to December 2015. Enrolled subjects were further randomly subdivided into three groups according to the dose regimen of lactoferrin supplementation. Early lactoferrin group (60) Preterm neonates received oral BLF 100 mg/day starting on day 1 and continued for 4–6 weeks or discharge whichever comes first. Late lactoferrin group (60) Preterm neonates received oral BLF 100 mg/day starting on day 3 (48hrs-72hrs) of life and continued as in early lactoferrin group. Control group (60) Preterm neonates received placebo in form of distilled water starting on day 1. History and clinical examination were carried out laying stress on signs of sepsis according to Tollner score; and laboratory investigations, CBC with differential cell count classified according to hematological scoring system (Rodwell score), CRP, blood culture and arterial blood gases when clinically indicated. Serum ferritin was done on day 14 of age. Radiological investigations were done when clinically indicated, data were analyzed using the statistical package for social sciences (SPSS).

**Results:** Early lactoferrin group included 25 males (41.7%) and 35 females (58.3%) with mean gestational age ( $32.37 \pm 1.31$  weeks). Late

lactoferrin group included 23 males (38.3%) and 37 females (61.7%) with mean gestational age ( $32.58 \pm 1.54$  weeks). Control group included 33 males (55.0%) and 27 females (45.0%) with mean gestational age ( $32.45 \pm 1.56$  weeks). the incidence of late onset sepsis was significantly lower in early (10%) and late (26.7%) lactoferrin groups compared to control group (45%). Coagulase-negative staphylococci and Klebsiella were the most common organisms found among the septic neonates in the current study (38%, 26% respectively). There were highly significant decrease in age of full enteral intake among early lactoferrin group with mean value ( $10.04 \pm 2.75$ ) days compared to late lactoferrin group and control group with mean values ( $12.15 \pm 2.75$ ) days and ( $14.43 \pm 4.47$ ) days respectively.

Also there were highly significant reduction in total days of feeding stoppage among early and late lactoferrin groups with mean values ( $2.14 \pm 1.75$  days), ( $3.47 \pm 1.82$  days) respectively compared to control group with mean values ( $4.92 \pm 3.65$  days), and among early lactoferrin group compared to late lactoferrin group. Moreover the results of the present study revealed that there were statistically significant increase in occurrence of abdominal distension in control group 48.3% as compared with early 1.7% and late 3.3% lactoferrin groups.

There were no statistically significant differences between studied groups as regard gastric residual, vomiting and diarrhea. Moreover, NEC incidence and staging showed no statistically significant differences between studied groups, nevertheless we can see the difference in the percentage of occurrence of NEC higher in the control group (6.7%) than that in early lactoferrin group (1.7%) and late lactoferrin group (3.3%). Also there were non-significant statistical differences between studied groups as regard incidence of broncho-pulmonary dysplasia, ROP and pulmonary hemorrhage. Also there were no statistically significant differences between studied groups as regard serum ferritin withdrawn in 2<sup>nd</sup> week of life.

Statistically significant decrease in mortality was detected among early lactoferrin group (3.3%) compared to control group (13.3%). In the current study the duration of total parenteral nutrition was significantly shorter in early lactoferrin group with mean value ( $4.24 \pm 2.66$  days) compared to control group with mean value ( $8.83 \pm 7.24$  days).

Also, NICU stay duration was significantly decreased in early and late lactoferrin groups with mean values ( $12.63 \pm 3.84$  days), ( $14.63 \pm 2.80$  days) respectively compared to control group with mean value ( $17.70 \pm 3.56$  days).

**Conclusion:** Preterm neonates supplemented with oral bovine lactoferrin had significantly lower incidence of late onset sepsis compared to control group. Oral bovine lactoferrin supplementation significantly decreased feeding intolerance, parenteral nutrition and NICU stay duration among preterm neonates. Early lactoferrin administration was significantly more effective than late lactoferrin administration in prevention of late onset sepsis.

**Keywords:** Lactoferrin, Neonatal sepsis, Preterm.